Sarcopenia News and Research

RSS

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

Tel Aviv University uncovers muscle-stem cell mechanism in aging

Working out can help you shed pounds ― but that's just the beginning. New research from Tel Aviv University has found that "endurance exercises," like a Central Park jog or a spinning class, can make us look younger. The key, exercise, unlocks the stem cells of our muscles.

2 Dec 2010

Amino acid mixture increases survival in mice

When mice are given drinking water laced with a special concoction of amino acids, they live longer than your average mouse, according to a new report in the October issue of Cell Metabolism, a Cell Press publication. The key ingredients in the supplemental mixture are so-called branched-chain amino acids, which account for 3 of the 20 amino acids (specifically leucine, isoleucine, and valine) that are the building blocks of proteins.

6 Oct 2010

Nutritional recommendations for management of sarcopenia published

Nutritional recommendations for the management of sarcopenia -- also described as age-related muscle and functional loss -- were published this past week in the clinical publication, Journal of American Medical Directors Association.

31 Aug 2010

Major bone-related meetings to take place in Valencia, Spain in March 2011

Two bone-related meetings, jointly organized by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and International Osteoporosis Foundation will take place in Valencia, Spain in March 2011.

11 Aug 2010

Exercise, restricted-calorie diets help to stave off mental, physical degeneration of aging: Research

Harvard University researchers have uncovered a mechanism through which caloric restriction and exercise delay some of the debilitating effects of aging by rejuvenating connections between nerves and the muscles that they control.

3 Aug 2010

Good muscle mass, strength and diet needed to stave off diabetes

Sarcopenia - low skeletal muscle mass and strength - is often found in obese people and older adults; it has been hypothesized that sarcopenia puts individuals at risk for developing Type 2 diabetes.

28 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

NIAMS, NINDS announce 5-year, $7.5M natural history study of Duchenne muscular dystrophy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to facilitate the development of promising new therapies for people with the disease.

10 May 2010

Dietary protein for overall health

The importance of high-quality protein foods in overall health was among the topics discussed this week at Experimental Biology 2010 in Anaheim, Calif. Researchers from a variety of institutions discussed studies that looked at varying levels of dietary protein intake to promote health throughout life including the role of protein in weight loss and muscle maintenance.

3 May 2010

New theory on muscle and bone diseases

Traditionally, doctors and clinicians thought diseases that affect muscles or bones affected those areas specifically. For example, bone diseases only affect bones, or muscle diseases only concerned muscles. But recent evidence supports the notion that bones and muscles are more interconnected than previously thought.

29 Apr 2010

Lean mass may decline among Alzheimer's patients

Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Individuals with higher midlife BMI scores have lower cognitive ability: Study

The adverse affects of being overweight are not limited to physical function but also extend to neurological function, according to research in the latest issue of the Journals of Gerontology Series A: Biological and Medical Sciences (Volume 65A, Number 1).

24 Feb 2010

Muscle-preserving therapy development may help young men keep muscle shirts a bit longer

Hey guys, remember the muscle shirts we wore in our teens and 20s? After the age of 40 that meager part of our wardrobes usually is obsolete. Yes, at the big 4-0 we begin to lose muscle, and by age 80 up to a third of it may be gone. It's an inevitable process of aging called sarcopenia.

15 Feb 2010

Scientists identify the cause of age-related muscle loss

If you're an aging baby boomer hoping for a buffer physique, there's hope. A team of American scientists from Texas and Michigan have made a significant discovery about the cause of age-related muscle atrophy that could lead to new drugs to halt this natural process. This

5 Jan 2010

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anabolic agents such as Selective Androgen Receptor Modulators (SARMs) are being sold on the black market for their performance enhancing qualities.

19 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009